Contents of Kit
1.Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96) MTP, 1 frame, the coating material is inactivated, 12
2.Standard serum (ready-to-use) STD Human serum in phosphate buffer with protein; negative for anti-HIV-Ab, HBs-Ag (Hepatitis B-Virus-surface antigen) and anti-HCV-Ab; preservative: < 0.1 % sodium azide, colouring: Amaranth O, 2 x 2 ml
3.Negative control serum (ready-to-use) NEG Human serum in phosphate buffer with protein; negative for anti-HIV-Ab, HBs-Ag (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, colouring: Lissamin green V, 2 ml
4.Anti-human-IgA-conjugate (ready-to-use) APC Anti-human-IgA from goat (polyclonal), conjugated to alkaline phosphatase, stabilized with protein stabilization solution, preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane, 13 ml
5.Washing solution concentrate (sufficient for 1 litre) WASH Sodium chloride solution with Tween 20, 30 mM Tris, preservative: < 0.1 % sodium azide, 33.3 ml
6.Dilution buffer DILB Phosphate buffer with protein and Tween 20; preservative: < 0.1 % sodium azide 0.01 g/l Bromphenol blue sodium salt, 2 x 50 ml
7.Stopping solution STOP 1.2 N sodium hydroxide, 15 ml
8.Substrate (ready-to-use) pNPP Para-nitrophenylphosphate, solvent free buffer, preservative: < 0.1 % sodium azide, (Substrate in unopened bottle may have a slightly yellow coloring. This does not reduce the quality of the product!), 13 ml
9.Quality control certificate with standard curve and evaluation table INFO (quantification of antibodies in IU/ml or U/ml), 1
General Description
Herpes Simplex Virus 1 (HSV1) and Herpes Simplex Virus 2 (HSV2) are human pathogen DNA viruses belonging to the family of Herpesviridae.
Herpes viruses are globally spread. Primary infection can be caused by contact with infected persons (saliva or urogenital secretion), cross-placentally or iatrogenically through transfusions or transplantations. After primary infection, local ganglions show lifelong virus persistence, enabling the reactivation of latent infections.
The transmission of Herpes genitalis during delivery can progress subclinically. In most cases it leads to localized or disseminated sepsis-like diseases.
After primary infection, viruses persist in certain cell types (latent cycle) until reactivation (lytic cycle). Reactivation occasionally progresses without symptoms or with low pathology in immunocompetent persons whereas severe clinical complications occur in immunocompromised patients.